http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
-
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Immunocore (IMCR) appoints Travis Coy as CFO, Head of Corporate Development
-
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
-
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
-
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
-
Immunocore (IMCR) announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
-
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
-
Immunocore (IMCR) announces reimbursement agreement in England for KIMMTRAK for the treatment of HLA-A*02:01-positive adults
-
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
-
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
-
The Galien Foundation Honors 2024 Prix Galien Award Recipients
-
Immunocore to present at upcoming investor conferences
-
Immunocore reports third quarter financial results and provides a business update
-
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
-
Immunocore to present at the 2024 Cantor Global Healthcare Conference
-
Immunocore (IMCR) Announces CFO Transition
-
Immunocore announces transition of Chief Financial Officer
-
The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"
-
Immunocore reports second quarter financial results and provides a business update
-
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
-
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
-
The Galien Foundation Announces 2024 International Prix Galien and Prix Galien Italy Award Winners
-
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
Immunocore (IMCR) reports updated Phase 1 data of brenetafusp (IMC-F106C)
-
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
-
Immunocore to present at the Jefferies Global Healthcare Conference
-
Immunocore (IMCR) converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial of KIMMTRAK
-
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
-
Immunocore reports first quarter financial results and provides a business update
-
Immunocore announces upcoming presentation and posters at ASCO 2024
-
The Galien Foundation Announces 2024 Prix Galien International Awards Nominees
-
Immunocore to present at upcoming investor conferences
-
Immunocore to present at upcoming investor conferences
-
Immunocore presented two posters at CROI 2024
-
Immunocore to present at upcoming investor conferences
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
-
Immunocore (IMCR) announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab
-
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first
-
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
-
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
-
Immunocore (IMCR) Prices Upsized $350M Convertible Notes Offering
-
Immunocore Prices Upsized Convertible Senior Notes Offering
-
Immunocore (IMCR) Announces Proposed $300M Notes Offering
-
Immunocore Announces Proposed Convertible Senior Notes Offering
-
Immunocore (IMCR) announces strategic priorities and pipeline expansion
-
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
-
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
